Chaos Theory and Fractals: A forgotten name in Healthcare
About the Tickers: Corbus Pharmaceuticals Holdings, Inc. 
CRBP is a clinical-stage company focused on the development and commercialization of novel medicines designed to target the endocannabinoid system. The Company’s lead product candidate, lenabasum, is a novel, oral, selective cannabinoid receptor type 2 (CB2) agonist designed to provide an alternative to immunosuppressive medications in the treatment of chronic inflammatory and fibrotic diseases. Lenabasum is currently being evaluated in dermatomyositis and systemic lupus erythematosus. Corbus is also developing a pipeline of other preclinical drug candidates from its endocannabinoid system platform. Phase 3 trial of Lenabasum in Systemic Sclerosis was unsuccessful last year. Currently, a phase 3 trial in Dermatomyositis is scheduled to read out top line results by Q2 2021.
The Chart: Appears similar to Cassava
SAVA which also saw setbacks and plunged to about $1 a share. Can we use fractals and chaos theory to predict the price of CRBP stock in the near term? Possibly.
Corbus Pharmaceuticals (CRBP) is currently trading at about $2 a share. Cassava Sciences (SAVA) is trading at about $54 a share.
CRBP is a clinical-stage company focused on the development and commercialization of novel medicines designed to target the endocannabinoid system. The Company’s lead product candidate, lenabasum, is a novel, oral, selective cannabinoid receptor type 2 (CB2) agonist designed to provide an alternative to immunosuppressive medications in the treatment of chronic inflammatory and fibrotic diseases. Lenabasum is currently being evaluated in dermatomyositis and systemic lupus erythematosus. Corbus is also developing a pipeline of other preclinical drug candidates from its endocannabinoid system platform. Phase 3 trial of Lenabasum in Systemic Sclerosis was unsuccessful last year. Currently, a phase 3 trial in Dermatomyositis is scheduled to read out top line results by Q2 2021. The Chart: Appears similar to Cassava
SAVA which also saw setbacks and plunged to about $1 a share. Can we use fractals and chaos theory to predict the price of CRBP stock in the near term? Possibly.Corbus Pharmaceuticals (
CRBP) is currently trading at about $2 a share. Cassava Sciences (SAVA) is trading at about $54 a share. 
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.